OTCBB:AGNPF

Algernon Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy AGNPF

*Your capital is at risk

$0.248

-0.0513 (-17.12%)

At Close: Jul 31, 2026

Wall Street higher at midday following US economic data

12:28pm, Thursday, 27'th May 2021

12:27pm: Nasdaq joins the other indices in the green In the US, the Dow was up 148 points, 0.4%, to 34,471 at midday. The Nasdaq added 31 points, 0.2%, to 13,769, and the S&P 500 improved 14 points,

Algernon Pharmaceuticals points to new research at Hungary university showing potential for DMT as stroke treatment

08:28am, Thursday, 27'th May 2021

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) has pointed to a new study at the University of Szeged in Hungary, which points to the potential of psychedelic compound DMT to be used t

Algernon Pharmaceuticals receives positive feedback from US FDA for its DMT stroke program

09:48am, Monday, 17'th May 2021

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) said it had received positive feedback from the US Food and Drug Administration (FDA) on its plans to investigate the use of DMT in strok

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

07:00am, Monday, 17'th May 2021

VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received

Algernon Pharmaceuticals reports findings from Ifenprodil Phase 2b/3 coronavirus trial may be positive for idiopathic pulmonary fibrosis (IPF) study

08:47am, Wednesday, 12'th May 2021

Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:BTHCF) reported potential recent findings, which could be positive for its ongoing Phase 2 clinical trial of Ifenprodil for idiopathic pulmonary

Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

07:15am, Wednesday, 12'th May 2021

VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceut

Algernon Pharmaceuticals hits 50% of enrollment target for Phase 2 lung fibrosis and chronic cough trial of ifenprodil

09:19am, Tuesday, 11'th May 2021

Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:BTHCF) announced that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

07:01am, Tuesday, 11'th May 2021

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceut

Algernon Pharmaceuticals plans meeting with the US FDA to prepare for upcoming Phase 3 Ifenprodil coronavirus trial

09:04am, Thursday, 08'th Apr 2021

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) plans to file an End-of-Phase 2 meeting request for a potential Phase 3 trial using Ifenprodil to treat coronavirus (COVID-19). The co

Algernon Pharmaceuticals appoints Dr Steven L. Wolf as a consultant for its clinical research program for the treatment of stroke

11:05am, Tuesday, 06'th Apr 2021

Algernon Pharmaceuticals Inc. (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF) said it has appointed Dr Steven L. Wolf, a global expert in the field of Physical Therapy & Rehabilitation Medicine, as a consultant fo

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by